We want to share with you what we know, and what we don’t know, about aducanumab (marketed as Aduhelm). Join us in a Facebook Live presentation about aducanumab on August 9 at noon. You do not need a Facebook account to join the livestream event — visit facebook.com/wisconsinadrc/live at the time of the presentation to join. Ask questions live during the presentation, or email your questions ahead of time to adrc@medicine.wisc.edu.
Speaking:
Sanjay Asthana, MD, Wisconsin ADRC director
Cynthia Carlsson, MD, MS, Wisconsin ADRC Clinical Core leader and WAI director
Nathaniel Chin, MD, Wisconsin ADRC and WRAP medical director
Carey Gleason, PhD, MS, Inclusion of Under-Represented Groups Core leader
Fabu Carter, PhD, senior outreach specialist
Joining the Q&A panel discussion:
Sterling Johnson, PhD, WRAP principal investigator
Alternate TBD
About aducanumab: On June 7, the U.S. Food and Drug Administration (FDA) approved the drug aducanumab for the treatment of Alzheimer’s disease. It is the first new treatment approved for Alzheimer’s disease since 2003 and the first-ever approved treatment that targets an underlying cause of Alzheimer’s disease rather than manage symptoms.
This is a significant development for anyone affected by Alzheimer’s disease. Aducanumab’s passage, however, has raised controversy. Finding facts through the jumble of opinions shared in the media is overwhelming.
